Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Urologic Diseases 1Pancreatic Neoplasms 1Nephritis 1Neoplasms 1Melanoma 1Mastocytosis 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Kidney Diseases 1Immune System Diseases 1Hypoxia 1Glomerulonephritis, IGA 1Glomerulonephritis 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Autoimmune Diseases 1

Interventions

Gemcitabine 78Fluorouracil 27Oxaliplatin 24130-nm albumin-bound paclitaxel 24Leucovorin 18Capecitabine 15Albumin-Bound Paclitaxel 15S 1 (combination) 14Taxes 12Irinotecan 11pembrolizumab 9folfirinox 9Radiosurgery 9Radiotherapy 7Drug Therapy 7Cisplatin 7irinotecan sucrosofate 6Pancreaticoduodenectomy 5Paclitaxel 5Injections 5Docetaxel 5Blood Specimen Collection 5apatinib 4Radiofrequency Ablation 4Radiation 4Biopsy 4tislelizumab 3rubitecan 3nimotuzumab 3camrelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Neoplasms × Hydroxychloroquine × Clear all
NCT01494155 2021-02-02

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Unknown
50 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡